Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro

Chelsea Gootjes, Jaap Jan Zwaginga, Tatjana Nikolic, Bart O Roep · 2026

Read Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro by Chelsea Gootjes, Jaap Jan Zwaginga, Tatjana Nikolic, Bart O Roep (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351131.txt.

Description

A lab-made antibody called iscalimab was meant to calm autoimmunity by blocking a key immune handshake, yet trials in transplantation disappointed. Chelsea Gootjes and colleagues tested a copy of the antibody on T cells in dishes to see whether T cell control was the weak point, in this 2026 PLOS One study.

The antibody bound its targets and completely stopped B cell growth, matching earlier reports. But it barely slowed diabetes-linked T cell clones that attack insulin-making cells, and it did not curb fresh T cell responses either. The authors argue this blind spot may explain the limited clinical benefit seen so far.

Catalog record

CREATORChelsea Gootjes, Jaap Jan Zwaginga, Tatjana Nikolic, Bart O Roep
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25175
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0351131

Browse the full library · About the Tower of Babel